Abstrakt

Przypisy

• 1. Anuszewska E.L., Gruber B.M., Koziorowska J.H.: Studies on adaptationto adriamycin in cells pretreated with hydrogen peroxide.Biochem. Pharmacol., 1997; 54: 597-603
  Google Scholar
• 2. Asakura T., Ohkawa K., Takahashi N., Takada K., Inoue T., YokoyamaS.: Glutathione-doxorubicin conjugate expresses potent cytotoxicityby suppression of glutathione S-transferase activity: comparisonbetween doxorubicin-sensitive and -resistant rat hepatomacells. Br. J. Cancer, 1997; 76: 1333-1337
  Google Scholar
• 3. Bailey H.H.: L-S,R-buthionine sulfoximine: historical developmentand clinical issues. Chem. Biol. Interact., 1998; 111: 239-254
  Google Scholar
• 4. Bailey H.H., Gipp J.J., Ripple M., Wilding G., Mulcahy R.T.: Increasein γ-glutamylcysteine synthetase activity and steady-state messengerRNA levels in melphalan-resistant DU-145 human prostatecarcinoma cells expressing elevated glutathione levels. Cancer Res.,1992; 52: 5115-5118
  Google Scholar
• 5. Bellamy W.T., Dalton W.S., Meltzer P., Dorr R.T.: Role of glutathioneand its associated enzymes in multidrug-resistant humanmyeloma cells. Biochem. Pharmacol., 1989; 38: 787-793
  Google Scholar
• 6. Binaschi M., Bigioni M., Cipollone A., Rossi C., Goso C., MaggiC.A., Capranico G., Animati F.: Anthracyclines: selected new developments.Curr. Med. Chem. Anticancer Agnets, 2001; 1: 113-130
  Google Scholar
• 7. Binaschi M., Farinosi R., Borgnetto M.E., Capranico G.: In vivo sitespecificity and human isoenzyme selectivity of two topoisomeraseII-poisoning anthracyclines. Cancer Res., 2000; 60: 3770-3776
  Google Scholar
• 8. Borst P., Evers R., Kool M., Wijnholds J.: A family of drug transporters:the multidrug resistance-associated proteins. J. Natl. CancerInst., 2000; 92: 1295-1302
  Google Scholar
• 9. Calvert P., Yao K.S., Hamilton T.C., O’Dwyer P.J.: Clinical studiesof reversal of drug resistance based on glutathione. Chem. Biol. Interact.,1998; 111-112: 213-224
  Google Scholar
• 10. Cao W., Zuo J., Meng Y., Wei Q., Shi Z.H., Ju L.M., Fang F.D.: Anticancerdrug resistance of HeLa cells transfected with rat glutathioneS-transferase pi gene. Biomed. Environ. Sci., 2003; 16: 157-162
  Google Scholar
• 11. Cole S.P., Downes H.F., Mirski S.E., Clements D.J.: Alterationsin glutathione and glutathione-related enzymes in a multidrug–resistant small cell lung cancer cell line. Mol. Pharmacol., 1990;37: 192-197
  Google Scholar
• 12. Depeille P., Cuq P., Passagne I., Evrard A., Vian L.: Combinedeffects of GSTP1 and MRP1 in melanoma drug resistance. Br. J. Cancer,2005; 93: 216-223
  Google Scholar
• 13. Drew R., Miners J.O.: The effects of buthionine sulphoximine(BSO) on glutathione depletion and xenobiotic biotransformation.Biochem. Pharmacol., 1984; 33: 2989-2994
  Google Scholar
• 14. Estrela J.M., Ortega A., Obrador E.: Glutathione in cancer biologyand therapy. Crit. Rev. Clin. Lab. Sci., 2006; 43: 143-181
  Google Scholar
• 15. Fojo T., Bates S.: Strategies for reversing drug resistance. Oncogene,2003; 22: 7512-7523
  Google Scholar
• 16. Franco R., Cidlowski J.A.: Apoptosis and glutathione: beyond anantioxidant. Cell Death Differ., 2009; 16, 1303-1314
  Google Scholar
• 17. Franco R., Cidlowski J.A.: Glutathione efflux and cell death. Antiox.Red. Sig., 2012; 17: 1694-1713
  Google Scholar
• 18. Franco R., Cidlowski J.A.: SLCO/OATP-like transport of glutathionein FasL-induced apoptosis: glutathione efflux is coupled to anorganic anion exchange and is necessary for the progression of theexecution phase of apoptosis. J. Biol. Chem., 2006; 281: 29542-29557
  Google Scholar
• 19. Furusawa S., Kimura E., Kisara S., Nakano S., Murata R., TanakaY., Sakaguchi S., Takayanagi M., Takayanagi Y., Sasaki K.: Mechanismof resistance to oxidative stress in doxorubicin resistant cells. Biol.Pharm. Bull., 2001; 24: 474-479
  Google Scholar
• 20. Gartenhaus R.B., Prachand S.N., Paniaqua M., Li Y., Gordon L.I.:Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistantmyeloma cell lines: enhancement of apoptosis by manipulation ofcellular redox state. Clin. Cancer Res., 2002; 8: 566-572
  Google Scholar
• 21. Gewirtz D.A.: A critical evaluation of the mechanisms of actionproposed for the antitumor effects of the anthracycline antibioticsadriamycin and daunorubicin. Biochem. Pharmacol., 1999;57: 727-741
  Google Scholar
• 22. Griffith O.W.: Mechanism of action, metabolism, and toxicityof buthionine sulfoximine and its higher homologs, potent inhibitorsof glutathione synthesis. J. Biol. Chem., 1982; 257: 13704-13712
  Google Scholar
• 23. Hayes J.D., Strange R.C.: Glutathione S-transferase polymorphismsand their biological consequences. Pharmacology, 2000;61: 154-166
  Google Scholar
• 24. Huang Z.Z., Chen C., Zeng Z., Yang H., Oh J., Chen L., Lu S.C.:Mechanism and significance of increased glutathione level in humanhepatocellular carcinoma and liver regeneration. FASEB J.,2001; 15: 19-21
  Google Scholar
• 25. Kamencic H., Lyon A., Paterson P.G., Juurlink B.H.: Monochlorobimanefluorometric method to measure tissue glutathione. Anal.Biochem., 2000; 286: 35-37
  Google Scholar
• 26. Katrusiak A.E., Paterson P.G., Kamencic H., Shoker A., Lyon A.W.:Pre-column derivatization high-performance liquid chromatographicmethod for determination of cysteine, cysteinyl-glycine, homocysteineand glutathione in plasma and cell extracts. J. Chromatogr.B Biomed. Sci. Appl., 2001; 758: 207-212
  Google Scholar
• 27. Kawanishi S., Hiraku Y., Pinlaor S., Ma N.: Oxidative and nitrativeDNA damage in animals and patients with inflammatory diseasesin relation to inflammation-related carcinogenesis. Biol. Chem.,2006; 387: 365-372
  Google Scholar
• 28. Kim H.M., Oh G.T., Hong D.H., Kim M.S., Kang J.S., Park S.M.,Han S.B.: MDR-1 gene expression is a minor factor in determiningthe multidrug resistance phenotype of MCF7/ADR and KB-V1 cells.FEBS Lett., 1997; 412: 201-206
  Google Scholar
• 29. Krzysztoń-Russjan J., Książek I., Anuszewska E.: Porównanieużyteczności testów MTT i EZ4U stosowanych do oceny cytotoksycznościksenobiotyków. Farm. Pol., 2009; 65: 395-402
  Google Scholar
• 30. Lai G.M., Moscow J.A., Alvarez M.G., Fojo A.T., Bates S.E.: Contributionof glutathione and glutathione-dependent enzymes in thereversal of adriamycin resistance in colon carcinoma cell lines. Int.J. Cancer, 1991; 49: 688-695
  Google Scholar
• 31. Leslie E.M., Deeley R.G., Cole S.P.: Toxicological relevance of themultidrug resistance protein 1, MRP1 (ABCC1) and related transporters.Toxicology, 2001; 167: 3-23
  Google Scholar
• 32. Liu J., Chen H., Miller D.S., Saavedra J.E., Keefer L.K., JohnsonD.R., Klaassen C.D., Waalkes M.P.: Overexpression of glutathione S–transferase II and multidrug resistance transport proteins is associatedwith acquired tolerance to inorganic arsenic. Mol. Pharmacol.,2001; 60: 302-309
  Google Scholar
• 33. Maciążek M.: Badanie dynamiki zmian stężenia tioli w mózguszczura po podaniu Selolu 10%. Master thesis at Faculty of Pharmacyof Medical University of Warsaw, 2007
  Google Scholar
• 34. Manna S.K., Kuo M.T., Aggarwal B.B.: Overexpression ofγ-glutamylcysteine synthetase suppresses tumor necrosis factor–induced apoptosis and activation of nuclear transcription factor-κBand activator protein-1. Oncogene, 1999; 18: 4371-4382
  Google Scholar
• 35. McLellan L.I., Wolf C.R.: Glutathione and glutathione-dependentenzymes in cancer drug resistance. Drug Resist. Update, 1999;2: 153-164
  Google Scholar
• 36. Meister A.: Glutathione metabolism. Methods Enzymol., 1995;251: 3-7
  Google Scholar
• 37. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L.: Anthracyclines:molecular advances and pharmacologic developmentsin antitumor activity and cardiotoxicity. Pharmacol. Rev., 2004; 56:185-229
  Google Scholar
• 38. Moral A., Palou J., Lafuente A., Molina R., Piulachs J., Castel T.,Trias M.: Immunohistochemical study of alpha, mu and pi classglutathione S transferase expression in malignant melanoma. Br. J.Dermatol., 1997; 136: 345-350
  Google Scholar
• 39. Mulcahy R.T., Bailey H.H., Gipp J.J.: Up-regulation ofγ-glutamylcysteine synthetase activity in melphalan-resistant humanmultiple myeloma cells expressing increased glutathione levels.Cancer Chemother. Pharmacol., 1994; 34: 67-71
  Google Scholar
• 40. O’Brien M., Kruh G.D., Tew K.D.: The influence of coordinate overexpressionof glutathione phase II detoxification gene products ondrug resistance. J. Pharmacol. Exp. Ther., 2000; 294: 480-487
  Google Scholar
• 41. Oguchi H., Kikkawa F., Kojima M., Maeda O., Mizuno K., SuganumaN., Kawai M., Tomoda Y.: Glutathione related enzymes incis-diamminedichloroplatinum (II)-sensitive and-resistant humanovarian carcinoma cells. Anticancer Res., 1994; 14: 193-200
  Google Scholar
• 42. Paumi C.M., Ledford B.G., Smitherman P.K., Townsend A.J, MorrowC.S.: Role of multidrug resistance protein 1 (MRP1) and glutathioneS-transferase A1-1 in alkylating agent resistance. Kineticsof glutathione conjugate formation and efflux govern differentialcellular sensitivity to chlorambucil versus melphalan toxicity. J. Biol.Chem., 2001; 276: 7952-7956
  Google Scholar
• 43. Ploemen J.H., Van Ommen B., Bogaards J.J., Van Bladeren P.J.:Ethacrynic acid and its glutathione conjugate as inhibitors of glutathioneS-transferases. Xenobiotica, 1993; 23: 913-923
  Google Scholar
• 44. Ploemen J.H., Van Schanke A., Van Ommen B., Van BladerenP.J.: Reversible conjugation of ethacrynic acid with glutathione andhuman glutathione S-transferase PI-1. Canc. Res., 1994; 54: 915-919
  Google Scholar
• 45. Ramachandran C., Samy T.S., Huang X.L., Yuan Z.K., KrishanA.: Doxorubicin-induced DNA breaks, topoisomerase II activity andgene expression in human melanoma cells. Biochem. Pharmacol.,1993; 45: 1367-1371
  Google Scholar
• 46. Ramachandran C., Yuan Z.K., Huang X.L., Krishan A.: Doxorubicinresistance in human melanoma cells: MDR-1 and glutathioneS-transferase π gene expression. Biochem. Pharmacol., 1993; 45:743-751
  Google Scholar
• 47. Riddick D.S., Lee C., Ramji S., Chinje E.C., Cowen R.L., WilliamsK.J., Patterson A.V., Stratford I.J., Morrow C.S., Townsend A.J., JounaidiY., Chen C.S., Su T., Lu H., Schwartz P.S., Waxman D.J.: Cancerchemotherapy and drug metabolism. Drug Metab. Dispos., 2005;33: 1083-1096
  Google Scholar
• 48. Sawyer T.E., Bonner J.A.: The interaction of buthionine sulphoximide(BSO) and the topoisomerase I inhibitor CPT-11. Br. J. CancerSuppl., 1996; 27: S109-S113
  Google Scholar
• 49. Schadendorf D., Makki A., Stahr C., van Dyck A., Wanner R.,Scheffer G.L., Flens M.J., Scheper R., Henz B.M.: Membrane transportproteins associated with drug resistance expressed in humanmelanoma. Am. J. Pathol., 1995; 147: 1545-1552
  Google Scholar
• 50. Shen D., Cardarelli C., Hwang J., Cornwell M., Richert N., IshiiS., Pastan I., Gottesman M.M.: Multiple drug-resistant human KBcarcinoma cells independently selected for high-level resistance tocolchicine, adriamycin, or vinblastine show changes in expressionof specific proteins. J. Biol. Chem., 1986; 261: 7762-7770
  Google Scholar
• 51. Sies H.: Glutathione and its role in cellular functions. Free RadicalBiol. Med., 1999; 27: 916-921
  Google Scholar
• 52. Strange R.C., Spiteri M.A., Ramachandran S., Fryer A.A.: Glutathione-S-transferase family of enzymes. Mutat. Res., 2001; 482: 21-26
  Google Scholar
• 53. Tipnis S.R., Blake D.G., Shepherd A.G., McLellan L.I.: Overexpressionof the regulatory subunit of g-glutamylcysteine synthetase inHeLa cells increases g-glutamylcysteine synthetase activity andconfers drug resistance. Biochem. J., 1999; 337: 559-566
  Google Scholar
• 54. Townsend D.M., Tew K.D.: The role of glutathione-S-transferasein anti-cancer drug resistance. Oncogene, 2003; 22: 7369-7375
  Google Scholar
• 55. Toyokuni S., Okamoto K., Yodoi J., Hiai H.: Persistent oxidativestress in cancer. FEBS Lett., 1995; 358: 1-3
  Google Scholar
• 56. Traverso N., Ricciarelli R., Nitti M., Marengo B., Furfaro A.L.,Pronzato M.A., Marinari U.M., Domenicotti C.: Role of glutathionein cancer progression and chemoresistance. Oxid. Med. Cell. Longev.,2013; 2013: 972913
  Google Scholar
• 57. Yao K.S., Godwin A.K., Johnson S.W., Ozols R.F., O’Dwyer P.J.,Hamilton T.C.: Evidence for altered regulation of γ-glutamylcysteinesynthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res., 1995;55: 4367-4374
  Google Scholar

Pełna treść artykułu